To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4 -14 recurrences per year received injections of both glycoproteins in MF59 adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study months, the rate and number of recurrences, the duration and severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic reactions were determined. The monthly rate of recurrences was not significantly improved, but the duration and severity of the first study outbreak was reduced significantly by vaccination. Glycoproteinspecific and neutralizing antibodies were boosted by vaccination for the duration of the study. This vaccine is safe and immunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not reduce recurrence frequency.
and immunotherapeutic vaccines would constitute a substantial
Study design. This was a randomized double-blind, placebopublic health advance [8] .
controlled trial conducted in two centers, the University of WashIn recent years, efforts at creating vaccines for genital herpes ington (Seattle) and the National Institutes of Health Clinical Cenhave concentrated on the administration to experimental aniter (Bethesda, MD). Randomization was stratified by center and mals and human subjects of recombinant herpes simplex virus by sex. Participants were randomly assigned to receive deltoid injections of MF59 placebo alone or of 10 mg each of gD2 and type 2 (HSV-2) envelope glycoproteins D and B (gD2, gB2), gB2 (gD2/gB2) in MF59 at entry and again at months 2, 12, which are known to elicit potent humoral and cellular immune and 14. One group, termed the placebo-first or ''placebo'' group, responses [9 -20] . These preliminary studies documented that received MF59 alone at months 0 and 2 but were crossed over to such vaccines are useful candidates for fuller exploration in receive gD2/gB2 in MF59 at months 12 and 14. The other group large-scale, controlled trials. The present report summarizes of patients, the vaccine-first or ''vaccine'' group, received gD2/ the results of a placebo-controlled trial of recombinant gD2 and gB2 in MF59 at months 0, 2, and 12 and MF59 alone at month gB2 in MF59, a novel oil-in-water adjuvant, for the treatment of 14 . Thus, all subjects knew they were to receive at least two doses established genital herpes. of gD2/gB2, including one at month 12. This design was thought to permit subject retention through 18 months of study to allow accrual of safety data on repeated vaccination. The truly blinded immunization, but acyclovir was allowed (200-mg capsules, five Genital herpes recurrences were assessed by uniformly applied criteria [19] . A recurrence could be confirmed either or both by 
reactions. Among the placebo recipients, 7 others withdrew to
Immunologic studies. Western blotting for documentation of resume acyclovir or because they moved from the study area;
HSV-2-specific antibodies, quantitation of gB2-specific and gD2- were culture-positive. Among gD2/gB2 recipients, there were 418 reported recurrences (10% fewer); 342 were clinically confirmed recurrences (8% fewer), and 175 of these were culture-positive (18% fewer). None of these differences was recipients had 5% -15% fewer recurrences than MF59
virus glycoproteins gD2/gB2 with MF59 (hatched bars). Those inirecipients -again, statistically insignificant reductions. In the tially assigned to receive gD2/gB2/MF59 received 3 doses of vaccine (V) followed by 1 dose of MF59 placebo (P). MF59 placebo-first absence of substantial differences in the rate of recurrences in recipients received 2 doses of placebo (P) followed by 2 containing the blinded study phase, it was not possible to discern or com-
ment on trends in recurrence rates in months 12 -18. During the first 8 months after vaccination, 81% of placebo recipients experienced a culture-proven recurrence; only 70% of gB2/gD2 recipients recurred. The relative risk of having a gD2/gB2 recipients than for placebo recipients, all statistically culture-positive recurrence for gB2/gD2 recipients was 0.64 insignificant differences (table 2). In the first 8 months of the (90% confidence interval, 0.46 -0.89; P Å .007), or 36% lower study, there were 464 lesional recurrences reported by placebo than that of placebo recipients. For the first 12 months of the recipients, of which 372 were clinically confirmed; 214 of these study, the relative risk of having a culture-positive recurrence was 0.68 (95% confidence interval, 0.50 -0.93; P Å .02) for vaccine recipients. those who were finally given it during the second, open phase of the study (the placebo-first group). Fifty-nine percent of subjects experienced a ú4-fold geometric mean rise in gB2-specific antibody titers; although the titers fell somewhat by month 12, the geometric mean gB2-specific titers remained nearly twice what they were at study entry (figure 2, top). Comparable boosting of gD2-specific antibodies was also seen, with Ç56% of recipients achieving a ú4-fold augmentation in titer (figure 2, middle). Neutralizing antibodies to HSV-2 rose by a geometric mean of nearly 2-fold with glycoprotein vaccination: 46% and 17% of subjects had ú2-fold and ú4-fold boosts in neutralizing antibodies, respectively (figure 2, bottom). Again, these titers remained increased for the entire duration of the study.
It is important to note that initial, peak, and final antigenspecific and neutralizing antibody titers did not correlate with outbreak frequency or the duration of virus shedding, lesional symptoms, or healing.
Discussion
Several decades of clinical anecdote and casual study suggested that vaccines may ameliorate recurrent HSV disease [26 -35] . A critical test of this possibility involved the administration of purified and recombinant glycoproteins D or B (or both) to guinea pigs who had been previously infected genitally with HSV-2. Depending on the adjuvant used and the vaccine composition, Stanberry and colleagues [12, 15] , Ho et al. [17] , and Burke [23] reported reductions in outbreak frequency of 25% -70% in infected guinea pigs. Clinical trials leading up of genital herpes disease [18 -20] .
l, gB2/gD2-first recipients; ᮀ, MF59 placebo-first recipients. Those Initial trials in infected patients involved recombinant gD2 initially assigned to receive gD2/gB2/MF59 received 3 doses of vacalone in the traditional alum adjuvant. Three doses given over cine (V) followed by 1 dose of MF59 placebo (P). MF59 placebo-first 12 months were well-tolerated and enhanced both humoral and recipients received 2 doses of placebo (P) followed by 2 containing cellular immune responses to HSV-2 [18] . gD2-specific titers glycoproteins (V).
were boosted 8-to 25-fold, while neutralizing responses rose 4-to 6-fold. There were concomitant increases in the proportion of peripheral blood mononuclear cells that proliferated in vitro shown). Significant amelioration of the clinical end points of these first study outbreaks was also evident if only culturein response to HSV antigens (Tigges M, unpublished data). A placebo-controlled trial was then conducted in which 100 proven recurrences were analyzed and if all lesional outbreaks were analyzed, whether clinically confirmed or not (data not mg of recombinant gD2 in alum was given at 0 and 2 months to 98 patients with recurrent genital herpes [19] . With just shown). Although there were consistent trends through all of these analyses for shorter durations of viral shedding among these two immunizations, gD2-specific titers were boosted an average of 7-fold, and neutralizing titers increased nearly 4-gD2/gB2 recipients, none of the differences was statistically significant.
fold. Notably, vaccination was associated with statistically significant but modest decreases in the median and total number Antibody responses. Vaccination led to prompt and sustained boosts in preexisting antigen-specific and neutralizing of recurrences. The monthly rates of recurrences were reduced by 24% and 36% for clinically confirmed and culture-proven antibody responses, in accord with earlier data (figure 2). Specifically, geometric mean antibody titers to HSV-2 glycoprotein episodes, respectively. Although that study was not designed to accurately assess the effect of vaccination on the duration B were boosted an average of 2.5-fold within 1 month of the second immunization with the glycoprotein-containing vaccine of outbreaks, patient diaries indicated a significant benefit (P Å .003; unpublished data). both in those who received it in the first study year and in / 9d39$$no32 09-03-97 12:20:42 jinfa UC: J Infect
In parallel with the controlled trial of recombinant gD2 in Among the possible reasons was the choice of a reduced and possibly suboptimal antigen dose (10 mg each of gD2 and alum, recombinant gD2 plus gB2 and a novel oil-in-water emulsion, MF59, entered clinical assessment. Studies showed gB2 in MF59 versus 100 mg of gD2 in alum) that would accommodate the greater reactogenicity of the MF59 adjuvant. that in previously uninfected persons, HSV-2 -specific immune responses are induced more rapidly and to higher levels with
In accord with this possibility was the lesser augmentation of HSV-2 -specific humoral responses in the present study than the addition of gB2 and with substitution of MF59 for alum [20] . Previously infected subjects sustained significant boosts in the gD2 in alum trial and, perhaps, also the more critical but unmeasured and still-undefined immune determinants of in gB2-specific antibodies, but neutralizing responses did not rise farther than they did with the alum-containing gD2 vaccine disease phenotype [18, 19] . This underscores, perhaps, the greater importance of antigen selection and dose than adjuvant (unpublished data). It was evident, however, that the rates and severity of local and systemic reactions to the gD2/gB2/MF59 in the design of therapeutic vaccines.
In conclusion, a vaccine composed of recombinant HSV-2 vaccines were greater than those seen earlier with the alum vaccine [18, 19] , especially in HSV-infected patients, and these glycoproteins D and B in an oil-in-water emulsion adjuvant led to significant amelioration of the first observed genital refindings were borne out in the present study (figure 1). On the basis of prior data, recombinant antigen concentrations of only currences, in further support of the concept of therapeutic vaccination for chronic viral diseases. A practical vaccine for disease 10 mg each were thought to lead to adequate immune responses in HSV-2 -seropositive subjects with acceptable reactogenimodification would also affect recurrence frequency. Perhaps newer technologies involving injections of viral DNA secity. Side effects were even more common with higher antigen doses; thus, the 10-mg dose of each antigen was chosen for the quences, immunostimulating cytokines, or genetically attenuated or replication-incompetent viruses would yield a practical present trial.
Here, in 202 patients with frequently recurring genital herimmunotherapeutic vaccine for genital herpes [36 -39] . pes, we documented that immunization had a consistent and highly significant impact on the first carefully studied postvac- the gD2 in alum vaccine in its preliminary analysis [19] .
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